Catumaxomab: in malignant ascites, PMID: 22676343
Catumaxomab: clinical development and future directions, PMID: 20190561
Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites, PMID: 20624115
Bispecific antibodies for cancer therapy: A review, PMID: 29269044
Catumaxomab: a bispecific trifunctional antibody, PMID: 19927225
The contribution of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer: a review of the literature, PMID: 23644922
Bispecific antibodies: design, therapy, perspectives, PMID: 29403265
Palliation of malignant ascites, PMID: 30903617
The evolving role of catumaxomab in gastric cancer, PMID: 18694358
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy, PMID: 20347527
Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines, PMID: 29970561
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study, PMID: 24965536
The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis, PMID: 20919824
Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study, PMID: 25367854
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy, PMID: 32989604
Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update, PMID: 29295696
Review of catumaxomab in the treatment of malignant ascites, PMID: 21188120
Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action, PMID: 20652245
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer, PMID: 29988111
Immunotherapy of peritoneal carcinomatosis with catumaxomab, PMID: 21358211
The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting, PMID: 23955093
Management of drainage for malignant ascites in gynaecological cancer, PMID: 31825525
Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature, PMID: 22744709
Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3), PMID: 26049121
Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab), PMID: 21716847
The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study, PMID: 24714773
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study, PMID: 25254563
Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab, PMID: 26296970
A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer, PMID: 25214034
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites, PMID: 21702044
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial, PMID: 20473913
Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients, PMID: 20565453
Alternative molecular formats and therapeutic applications for bispecific antibodies, PMID: 25637431
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study, PMID: 25225907
Catumaxomab: malignant ascites: unjustified marketing authorisation, PMID: 21180374
Molecule of the month: catumaxomab, PMID: 19609465
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3, PMID: 25814216
Structural and functional characterization of the trifunctional antibody catumaxomab, PMID: 20418662
Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report, PMID: 24380380
Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors, PMID: 27058902
Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo, PMID: 22551544
Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer, PMID: 23197249
Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer, PMID: 18535935
Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3), PMID: 22044753
Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer, PMID: 19443405
Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report, PMID: 23038231
First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam x anti-CD3) for epithelial ovarian cancer, PMID: 21778311
Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study, PMID: 17410361
Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study, PMID: 19238019
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial, PMID: 21358214
Catumaxomab: First Approval., PMID:40304879
Contemporary Management of Malignant Ascites., PMID:40037156
Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment., PMID:38644553
A pivotal decade for bispecific antibodies?, PMID:38465614
Using biomarkers to allocate patients in a response-adaptive clinical trial., PMID:38045870
Identification of potential therapeutic drugs targeting core genes for systemic lupus erythematosus (SLE) and coexisting COVID-19: Insights from bioinformatic analyses., PMID:38018597
Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes., PMID:37190310
Peritoneal carcinomatosis with intraperitoneal immunotherapy: current treatment options and perspectives., PMID:36107723
Construction of miRNA-regulated drug-pathway network to screen drug repurposing candidates for multiple sclerosis., PMID:35356949
Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study., PMID:34715784
Advances in the conventional clinical treatment for hepatoblastoma and therapeutic innovation., PMID:36474976
First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity., PMID:33837852
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy., PMID:32989604
Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines., PMID:32438548
Management of drainage for malignant ascites in gynaecological cancer., PMID:31825525
Engineering IgG-Like Bispecific Antibodies-An Overview., PMID:31544880
Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow., PMID:31011631
Palliation of malignant ascites., PMID:30903617
Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?, PMID:32634192
Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis., PMID:30364780
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis., PMID:30103457
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer., PMID:29988111
Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines., PMID:29970561
Bispecific antibodies: design, therapy, perspectives., PMID:29403265
Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update., PMID:29295696
Bispecific antibodies for cancer therapy: A review., PMID:29269044
Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives., PMID:28531111
The development of bispecific antibodies and their applications in tumor immune escape., PMID:28469973
Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition., PMID:27966460
Intraperitoneal immunotherapy: historical perspectives and modern therapy., PMID:27834358
The current status of immunotherapy in peritoneal carcinomatosis., PMID:27530056
Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors., PMID:27058902
Bispecific antibodies and their applications., PMID:26692321
Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms., PMID:26417039
Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab., PMID:26296970
Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects., PMID:26115884
Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3)., PMID:26049121
Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome., PMID:25991672
Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro., PMID:25947366
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3., PMID:25814216
Clinical pharmacology of bispecific antibody constructs., PMID:25707960
Alternative molecular formats and therapeutic applications for bispecific antibodies., PMID:25637431
A survey of treatment approaches of malignant ascites in Germany and Austria., PMID:25528551
Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinoma--a report of 2 cases., PMID:25427585
Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study., PMID:25367854
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study., PMID:25254563
Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study., PMID:25225907
A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer., PMID:25214034
An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro., PMID:25075094
Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study., PMID:24965536
For research use only. Not for human or drug use.
